The Use of Aromatherapy for the Treatment of Post-Operative Nausea Vomiting by Whitley, Mikayla J.
Portland State University 
PDXScholar 
University Honors Theses University Honors College 
5-24-2019 
The Use of Aromatherapy for the Treatment of Post-
Operative Nausea Vomiting 
Mikayla J. Whitley 
Portland State University 
Follow this and additional works at: https://pdxscholar.library.pdx.edu/honorstheses 
Let us know how access to this document benefits you. 
Recommended Citation 
Whitley, Mikayla J., "The Use of Aromatherapy for the Treatment of Post-Operative Nausea Vomiting" 
(2019). University Honors Theses. Paper 750. 
https://doi.org/10.15760/honors.767 
This Thesis is brought to you for free and open access. It has been accepted for inclusion in University Honors 
Theses by an authorized administrator of PDXScholar. For more information, please contact pdxscholar@pdx.edu. 
THE USE OF AROMATHERAPY FOR THE TREATMENT OF POST-OPERATIVE 






The Use of Aromatherapy for the Treatment of Post-Operative Nausea Vomiting  
Mikayla Whitley  
Melissa Schmidt  

























 Post-operative nausea vomiting (PONV) is one of the most common complications after 
surgery and a significant cause of dissatisfaction among post-operative patients. Traditional first 
line treatment of PONV with antiemetic medications can cause severe side effects and can have 
compounding interactions with other medications. Aromatherapy has been increasing in 
popularity for the treatment of PONV due to its safety, absence of drug interaction and side 
effects, and rapid onset due to ease of administration and patient driven treatment. This study 
looks at a trial of QueaseEASE, an aromatherapy product for PONV, at a hospital in the Pacific 
Northwest. Overall initial findings suggest high patient satisfaction of treatment with 
QueaseEASE. Preliminarily, the trial shows a reduction in the use of antiemetic medications, 
however, more data is needed to show statistical significance.  
 
Background  
 Post-operative nausea vomiting (PONV) is a common surgical complication, occurring in 
10%-30% of all patients and as high as 70% to 80% for high risk patients (Briggs, Hawrylack, & 
Mooney, 2016). Several risk factors for PONV have been identified such as being female, being 
a nonsmoker, having a history of PONV or motion sickness, and perioperative opiate exposure 
(Apfel, Läärä, Koivuranta, Greim, & Roewer, 1999). These risk factors are commonly used to 
create a PONV risk score with an addition of each variable predicting a greater likelihood 
someone will experience PONV. The pathways that lead to PONV can be complex and variable 
for different patients. The vomiting center in the brain lies in the medulla oblongata which can be 
stimulated by four areas: the gastrointestinal tract, cerebral cortex and thalamus, vestibular 
region, and chemoreceptor trigger zone (CRTZ) (Becker, 2010). Opiate medications received 
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during and after surgery can induce nausea and vomiting mainly through the CRTZ as well as the 
gastrointestinal tract (De Pradier, 2006). The CRTZ lies close to the vomiting center in the brain 
and is unique because it is not protected by the blood brain barrier like other brain structures 
(Becker, 2010). Chemical changes in the blood can affect the CRTZ and induce vomiting. The 
gastrointestinal induction of nausea and vomiting is produced by the loss in tone in the gastric 
fibers resulting in slowing the emptying of the stomach (De Pradier, 2006).  
 Antiemetics used to treat PONV can vary in effectiveness and often have undesired side 
effects (Briggs et al., 2016). The first class of common antiemetic medications used to treat 
PONV are dopamine antagonists such as prochlorperazine (Compazine) and metoclopramide 
(Reglan) which can be effective in treating most causes of PONV including stimulation from the 
CRTZ as well as the gastrointestinal tract (Becker, 2010). The potential harmful side effects from 
dopamine antagonists include sedation, hypotension, and extrapyramidal syndromes 
(Omudhome, 2017). The most common extrapyramidal syndrome caused by prochlorperazine is 
called akathisia which causes patients to feel restless and a compelling need to move (Becker, 
2010).  The next class of common antiemetic medications is 5-HT3 (serotonin) antagonists, the 
most commonly used is ondansetron (Zofran) (Becker, 2010). Some side effects of ondansetron 
include headache, lightheadedness, abnormal liver enzyme production, and arrhythmias 
(Williams, 2017).  Lastly, another common class of antiemetic medication used to treat PONV is 
antihistamines which include meclizine (Antivert) and scopolamine (Hyoscine) (ASPAN’s 
evidenced-based, 2006). Common side effects of these medications include sedation, dry mouth, 
blurred vision, and specifically Scopolamine can cause renal or hepatic impairment (ASPAN’s 
evidenced-based, 2006, Stoppler, 2019).  
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The sedative effects of many of the classes of antiemetic medications can disrupt a 
patient’s ability to cough and deep breathe which are critical when recovering from anesthesia 
(Briggs et al., 2016). If not successfully treated, PONV can lead to more severe post-operative 
complications such as dehydration, electrolyte disturbance, aspiration, and wound dehiscence. 
This can lead to increase post-anesthesia care unit (PACU) length of stay and unplanned hospital 
admission (Hines, Chang, Gibbons, 2018). PONV is one of the highest reported concerns among 
patients before surgery and one of the main causes of dissatisfaction from patients (Hines et al., 
2018). 
 Aromatherapy is described as the use of essential oils to treat physical or psychological 
symptoms (Herz, 2009). Two main mechanisms for how aromatherapy produces its effects have 
been proposed: the first being the pharmacological hypothesis, secondly the psychological 
hypothesis. The pharmacological hypothesis suggests that that the components of the essential 
oils directly interact and affect the nervous and endocrine system. Lavender, which is known for 
it’s calming and sedative effects, has been shown to act postsynactpically - where it has been 
proposed to regulate the activity of cyclic andenosine monophosphate (cAMP). The reduction of 
cAMP activity is correlated with sedation (Herz, 2009). Thus suggesting that lavender essential 
oil is acting through a neuropharmacological mechanism. Several other studies have shown that 
rats exposed to the vapors of essential oils have detectible levels of aromatic compounds in the 
blood stream. This suggests that these compounds could be absorbed by way of the nasal or lung 
mucosa and act pharmacologically (Herz, 2009). However, no studies in humans have shown 
inhaled vapors having any detectable compounds in the bloodstream or other physiological 
pathways. Another issue raised for the pharmacological hypothesis is it takes at least 20 minutes 
for a compound to circulate through the bloodstream and across the blood-brain barrier. Many 
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studies report responses to aromatherapy being immediate, which conflicts with the mechanism 
of action being via bloodstream (Herz, 2009).  
Another mechanism of action proposed by the pharmacological hypothesis is direct 
interaction of the odorants with neural substrates that would produce a more immediate response. 
In order for either mechanism to produce the physiological response there must be receptor-
ligand binding where the aromatic compound binds to a specific receptor site. This would 
suggest that the structure of the compound is crucial in producing the desired effect (Herz, 2009). 
Several studies have tested this structure-function relationship by using chemically identical 
molecules with different orientations. One study looked at the autonomic and self-evaluated 
measures of mood using enantiomers of limonene and carvone (Heuberger et al., 2001). The 
enantiomers were found to produce different autonomic and self-evaluated results, however, the 
difference in scent was detectible, so a perceptual-psychological contributing factor cannot be 
ruled out (Heuberger et al., 2001). Another study done by Kuroda (2005) and colleagues looked 
to eliminate this confounding variable by reducing the concentration of the odorant to below a 
detectible threshold. This study looked at enantiomers of linalool and found both physiological 
and psychological differences (Kuroda et al., 2005).  Despite these studies, there have been many 
others that looked at different variants of the same odor, often a natural and artificial one, and 
found similar physiological and psychological effects, suggesting that the perception of the 
odorant produces the aromatherapy effects (Herz, 2009).  
The psychological hypothesis proposes that aromatherapy has an effect through an 
emotional learning, perception, and belief/expectation. This hypothesis claims that the response 
to odors are produced by associative learning which is when events or items become linked to 
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one another through experience (Herz, 2005, 2009). Scents have long been known to be 
associated strongly with memories due to the proximity of the olfactory nerve to the amygdala 
that is responsible for expression and experience of emotion. The amygdala is also closely 
associated to the hippocampus, which transmits information from working memory to short-term 
and long-term memory (Herz, 2009). Multiple studies have shown that responses to odors can be 
produced by associative learning. One study showed that adult participants who were afraid of 
the dentist showed a fear response when exposed to the scent of eugenol (a common component 
of dental fillings) (Herz, 2005). Another example is a study done by the U.S. military to try and 
make a universal stink bomb but could not find a cross-culturally dislike of the scent (Herz, 
2005). Another compelling example for associative learning and odors is a study done in 1966 
that looked at perceptual responses to different common scents(Herz, 2005). They found in 
Britain wintergreen was one of the lowest rated scents, where in America it was one of the 
highest rated. This difference was explained by the use of wintergreen in Britain as a common 
flavor for medicine where in America it was exclusively used in candy and sweets (Herz, 2005). 
A study done by Epple & Herz (1999) showed that participants exposed to a novel odor when 
completing a difficult or frustrating task were later less motivated and subsequently spent less 
time willing to engage in a new unrelated task when re-exposed to the same odor. Another study 
found that the suggestion of a scent as producing a desired response was more important than the 
scent itself (Campenni, Crawley, & Meier, 2004). This study compared lavender, neroli, and a 
placebo, and examined changes in heart rate and skin conductance. They found that when the 
scent was suggested to be relaxing all three produced a decrease in heart rate and skin 
conduction; similarly, when the scents were suggested to be stimulating it was found that all 
three scents produced an increase in heart rate and skin conduction. The psychological 
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hypothesis for aromatherapy is currently the best model by which associated learning can 
produce emotional, behavioral and physiological effects (Herz, 2009).  
The use of aromatherapy to treat PONV has been commonly used in postanesthetic care 
units, mainly with isopropyl alcohol found in ‘prep-pads’. This practice is said to be a traditional 
South American nausea relief remedy, which has been widely used in American hospitals before 
studies that justified the clinical effectiveness (Hines et al., 2018). More recently, aromatherapy 
has been suggested as an alternative treatment for PONV due to its safety, lack of drug 
interaction and side effects, and rapid onset due to ease of administration and patient driven 
treatment (Asay, Olson, Donnelly, & Perlman, 2018). The use of aromatherapy could also 
provide a financial incentive to the hospital. Two of the most commonly used antiemetic 
medications: prochlorperazine and ondansetron cost an average of $13.99 and $51.98 
respectively in 2004 to successfully manage a patients PONV (Chang, 2005). The cost of one 
QueaseEASE tab that lasts 72 hours is $6 (Medical, n.d.). The American Society of 
PeriAnesthesia Nurses now includes aromatherapy in the clinical guidelines for treating PONV 
(ASPAN’S Evidence-Based, 2006).  
Literature Review  
 A large meta-analysis published in the Cochrane Database of Systematic Reviews, 
consisting of 16 different studies, conducted in March of 2018, looked at the use of aromatherapy 
with isopropyl alcohol (IPA), various essential oils, and blends to treat PONV (Hines et al., 2018). 
All of the studies were either randomized controlled trials or controlled clinical trials on 
postoperative patients in a PACU setting or day surgery unit.  The results were broken into four 
groups: summary of overall findings, peppermint compared to placebo, isopropyl alcohol 
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compared to the standard treatment, isopropyl alcohol compared to placebo. Overall, more patients 
who received aromatherapy as first line treatment for PONV compared to those who received a 
placebo were nausea free at the end of treatment. Another major finding was that fewer patients 
who received aromatherapy compared to a placebo required rescue antiemetic medications. It was 
also found, however, that there was no difference in the reduction of nausea severity in the 
aromatherapy groups vs. placebo (Hines et al., 2018). Of all the 16 studies used none reported any 
adverse events or allergic reactions. Of the studies that measured patient satisfaction, overall high 
levels of satisfaction were reported. Four of the 16 studies looked at peppermint compared to 
placebo with the meta-analysis showing little to no difference in the severity of nausea (Hines et 
al., 2018). Three studies looked at isopropyl alcohol compared to the standard of care and found 
that the aromatherapy group had significantly faster relief. The results also showed a reduction in 
the use of rescue antiemetics (Hines et al, 2018).  Lastly, three studies looked at isopropyl alcohol 
compared to a placebo, however, the meta-analysis on the severity of nausea was not able to be 
performed due to differenced in measuring and data reporting. The Cochrane Database of 
Systematic Review ultimately found that the quality of the evidence was low and that more 
research is needed. It was also concluded that there was insufficient evidence for the use of ginger 
or blends to treat PONV due to lack of data, but the authors noted positive results in individual 
studies. Finally, the authors concluded that aromatherapy may be a simple and inexpensive therapy 
but should be used complementary to pharmacological antiemetics (Hines et al., 2018).  
 Other reviews published after the Cochrane Review, such as one done in August of 2018, 
found that 3/5 studies reviewed had statistically significant results that the use of aromatherapy 
decreased PONV, with the most effective therapies using peppermint, ginger, or blend of 
peppermint, ginger, lavender, and spearmint oil (Asay et al., 2018). They also found overall high 
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patient satisfaction with the aromatherapy treatment. Another study not included in the Cochrane 
Review that was published around the same time looked at the use of QueaseEASE, an 
aromatherapy product that delivers a blend of peppermint, ginger, lavender, and spearmint oil, 
compared to the standard of care (Stallings-Welden et al., 2018). There was no perceived 
difference in the effectiveness or timeliness between the two treatment groups. In this study 
aromatherapy was found to be as effective as the standard of care but carries less risks that 
accompanies the use of antiemetics. Other studies done focused on patient satisfaction and quality 
improvement using QueaseEASE showing positive results (Amedio, 2016; Hodge, McCarthy, & 
Pierce, 2014; Malone, 2017) These studies showed higher patient satisfaction in the QueaseEASE 
treatment group as well as a reduction in the use of antiemetic medications.  
Thesis Question 
Does the use of aromatherapy to treat PONV decrease the use of recue antiemetics and/or PONV 
related hospitalizations? Additionally, are patients satisfied with the treatment of their PONV 
with aromatherapy?  
Theoretical Framework 
There are several key principles that guide process improvement in order to promote 
change in a healthcare setting. The first being that quality improvement is the science of process 
management. In a healthcare setting this amounts to focusing on one process at a time that needs 
improvement in order to make big changes in quality of care. (Haughom, 2016). The next 
principle is that if you can’t measure it you can’t improve it. In order for the trial of 
QueaseEASE to be found successful there must be quantitative and qualitative data to show that 
it is improving the goals set. Next, there must be the right data, in the right format, at the right 
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time. This can be a challenge because if there is not literature that help guides your process 
improvement, choosing the right data to look at can be daunting. Lastly, there must be 
engagement with clinicians for the change. If the team is not educated and onboard with the 
change then it won’t be successful (Haughom, 2016). In order to meet all these criteria for 
process improvement, Lippett’s change theory was chosen as a theoretical framework to analyze 
and promote the change of implementing an alternative first line treatment for PONV. Lippett’s 
change theory incorporates all the elements of successful process improvement and allows the 
change agent to organize the change in a scientific way. Lippett’s change theory consists of 
seven phases (Kritsonis, 2005):  
1. Diagnose the problem 
2. Assess the motivation and capacity for change 
3. Assess the resources and motivation of the change agent 
4. Choose progressive change objects including developing plans of action and strategies 
5. Determine the role of the change agent and that it is clearly understood by all parties so 
that expectations are clear 
6. Maintain the change including communication, feedback, and group coordination 
7. Gradually terminate from the helping relationship with gradual withdrawal of the change 
agent 
Phase 1 does not have a clearly defined start date because the need for effective antiemetic 
medications with limited side effects is ongoing. The proposed use of aromatherapy in the 
hospital of interest started in October 2018 with a peaked interest from a MAGNET presentation. 
To further diagnose the problem a baseline use of recuse antiemetic medication and 
hospitalizations due to PONV was determined. Phase 2 was motivated by a desire to provide 
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better holistic care to patients suffering from PONV. Interest from the PACU care team about 
aromatherapy led to the conclusion that there is capacity to change. A strength-weakness-
opportunity-threat (SWOT) analysis was constructed to assess barriers to change (Table 1). In 
phase 3 I identified my thesis advisor Melissa Schmidt as my main resource and the Nurse 
Clinical Leader of the PACU. In phase 4 the plan of action was determined to be a 60-unit trial 
of QueaseEASE with an associated questionnaire (Figure 1) to start in May 2019. Project leader 
Denise Smith was identified as an interested party to implement, guide, and preside over the trial. 
Objectives of this change is to reduce the use of rescue antiemetics and PONV related 
hospitalizations. Other objectives include evaluating nurse and patient satisfaction with 
aromatherapy treatment for PONV. In phase 5 I put together a presentation and was part of the 
education given to the nursing staff on the implementation of the aromatherapy and how to use 
the questionnaire. I evaluated and processed data collected from looking at charts and reviewing 
the questionnaires. My nurse clinical leader and I made everyone aware that I was a resource for 
questions and concerns about the implementation. Phase 6 will involve reflection and feedback 
on the aromatherapy to determine effectiveness and satisfaction. If and when effective 
implementation is established, Phase 7 can begin. Phase 7 must include securing QueaseEASE as 
a product that is being ordered regularly as well as implementing continued training for new 
nurses to the PACU. An overview of Lippett’s phases in respect to the project can be found in 
Figure 2. 
Methods  
In order to implement and maintain aromatherapy with QueaseEASE as a first line 
defense for PONV evidence was collected for the effectiveness in treating PONV, the use of 
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rescue antiemetics, and patient satisfaction. A retrospective evaluation was completed of the 
frequency of rescue antiemetics used in the PACU, PONV score, type of surgery, intraoperative 
antiemetic medication use, and hospitalizations due to PONV between January 1, 2019- April 1, 
2019. These measures were then compared after the implementation of QueaseEASE as first line 
PONV treatment with the use of a questionnaire. Patient perceived effectiveness and satisfaction 
with the product was also evaluated using the questionnaire (Figure 1). The first part of the 
questionnaire was administered at the bedside in the PACU. The second part of the questionnaire 
was administered in person on the ward or by phone call post-op. Nurse-education trained staff 
on how to administer the aromatherapy as well as how to use the questionnaire for evaluation. 
The training consisted of a 15 minute in-service with information on why aromatherapy was 
being trialed for the treatment of PONV, what the purpose of a trial period is, and how to 
administer and evaluate QueaseEASE. The PONV risk score of the pre-aromatherapy and post-
aromatherapy groups were compared using a paired t-test. The PONV severity score was 
compared before and after 5 minutes of QueaseEASE administration and a paired t-test was 
conducted to determine if there was a significant difference in the groups.   
Results 
 From the period of January 1, 2019 to April 1, 2019 there was 49 incidences of PONV 
with 94% of those patients receiving at least one form of prophylactic nausea treatment. The 
average number of prophylactic treatments given was 1.55 per patient. All of the patients who 
experienced nausea received at least one rescue antiemetic medication with the average number 
being 1.33 per patient. The average PONV risk score for this group was 2.14. There was one 
incident of a planned out-patient converting to inpatient from PONV in this timeframe.  
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 After the implementation of QueaseEASE, in the first month there was 12 incidences of 
PONV with 81% of those patients receiving at least one form of prophylactic treatment. The 
average PONV risk score of this group was 2.63; there was no significant difference in the risk 
score in the pre and post group (p> 0.10). The average number of rescue antiemetic medications 
given per patient after the implementation of QueaseEASE as first line PONV treatment was 0.5. 
A t-test was not able to be performed on the amount of rescue antiemetic medications used due 
to large difference in sample size. The average nausea rating before the aromatherapy treatment 
was 1.8 and after treatment was 1, however, there was no statistically significant difference in the 
ratings (p>0.05). The most common reported level of nausea after treatment was a 1 which was 
indicated as mild.  
 In the post-operative follow-up patients were asked to rate the effectiveness out of 5 and 
the average rating was 4.1. Overall 90% of patients said they would use QueaseEASE again.  
Discussion  
 Despite the difference in sample size, the results show a comparable PONV risk score as 
well as number of patients who received prophylactic antiemetic medications in the pre and post 
aromatherapy group; this leads to the belief that these groups are comparable to one another. 
There was a reduction in the average number of antiemetics given from 1.33 to 0.5 per patient, 
however, as mentioned before, a t-test was not able to be performed. These preliminary results 
support the continuation of Lippett’s change theory phase 6: maintain the change including 
communication, feedback, and group coordination. The change will remain with continued 
feedback from patients and staff, as well as continued data collection. One of the goals was to 
show if there was a reduction in the number on rescue antiemetics being used, the ability to show 
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that there is a significant difference would allow support to move to phase 7 where there would 
be termination of the helping relationship of the change agent. In order to reach phase 7, the 
hospital must acquire QueaseEASE as a regularly ordered product. The reduction in the use of 
more expensive rescue antiemetics will provide incentive for hospital executives to support this 
change. There was not a large enough sample to show if there was a reduction in hospitalization 
due to PONV.  
 There was variation in patients reported change in nausea with aromatherapy treatment. 
The most common nausea scale rating after treatment was mild (1). Some patients reported no 
change in the severity of nausea while others reported no nausea after treatment. The small 
sample size leads to the belief that there may not be enough data to show significant results. 
Again, this supports the continuation of phase 6 to allow for a larger amount of data.  
 The results show overall positive patient satisfaction with a rating of effectiveness of 
4.1/5 as well as 90% of patients saying that they would use QueaseEASE again. This combined 
with anecdotal evidence of patients expressing that they would like to be able to purchase their 
own, as well as one patient asking for more when he was continuing to experience post-discharge 
nausea while staying at the hospital, there is support for the change.  
Conclusion  
Aromatherapy for treatment of PONV has been increasing in popularity among hospitals 
and patients with increasing evidence for the effectiveness. Aromatherapy allows nurses to 
initiate treatment without a physician’s orders and allows patients alternative options and power 
in the decision making about their care. The data supports the continuation of Lippett’s phase 6 
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and suggests that complementary treatment with aromatherapy is well-received and provides a 





















Table 1: A Strength-weakness-opportunity-threat (SWOT) analysis is a good way to organize 











• Low risk intervention 
• Inexpensive intervention  
• Staff invested in improvement  
• Change agent committed to project 
success 
Weakness 
• Not well-established research on 
aromatherapy for PONV 
• Public misconception of aromatherapy  
• No literature standard for PONV scale 
Opportunities 
• Innovation on the unit level  
• Decrease use of rescue antiemetics 
• Decreased hospitalization due to PONV 
• CNA contribution to nurse improvement 
project   
Threats 
• Resistance of staff to change first line 
treatment  
• Patient refusal  
• Long process to acquire new product in 
the medical center  





Figure 1: Example questionnaire used to determine QueaseEASE effectiveness and patient 
satisfaction 
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